



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary D. Glick *et al.*

Group No.: 1618

Serial No.: 09/767,283

Examiner: Kim, Vickie Y.

Filed: 01/22/2001

Entitled: **Use of Benzodiazepines for Treating Autoimmune  
Disease Induced by Apoptosis**

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)**

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: January 23, 2006

By: 


Mary E. Waite

Sir or Madam:

Enclosed please find a Supplemental Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

Applicants believe that no fee is required. If the Commissioner deems otherwise, the Commissioner is hereby authorized to charge any additional fee, and/or credit any overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: January 23, 2006



Robert A. Goetz  
Registration No. 55,210

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
608/218-6900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


In re Application of: Gary D. Glick *et al.*  
Serial No.: 09/767,283  
Filed: 01/22/2001  
Entitled: **Therapeutic Applications Of Pro-Apoptotic  
Benzodiazepines**

Group No.:  
Examiner:



**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



Sir or Madam:


The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- US Patent 6,506,744, Issued 01/14/2003, Alig, et al
- US Patent 6,767,533, Issued 07/27/2004, Casellas, et al
- Parks, Daniel J. Bioorg Med Chem. Ltrs., 15,(2005), 765-770
- Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861
- Hulme, C. J. Org. Chem., 63,(1998), 8021-8023
- Kamal, A. Synlett, 14,(2004), 2533-35
- Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912
- Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484


- Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 1-23-2006  
January 23, 2006

  
Robert A. Goetz  
Registration No. 55,210  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
608/218-6900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 2

**Complete if Known**

Application Number	09/767,283
Filing Date	01/22/2001
First Named Inventor	GLICK, et al
Art Unit	1618
Examiner Name	Kim, Vickie Y
Attorney Docket Number	UM-07269

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US- 6,767,533	07/27/2004	Casellas	Whole Document
	2	US- 6,506,744	01/14/2003	Alig	Whole Document
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/767,283
Filing Date	01/22/2001
First Named Inventor	Glick
Art Unit	1618
Examiner Name	Kim, Vickie Y.
Attorney Docket Number	UM-07269



Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	3	Parks, Daniel J. Bioorg Med Chem. Ltrs., 15,(2005), 765-770	
	4	Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861	
	5	Hulme, C. J. Org. Chem., 63,(1998), 8021-8023	
	6	Kamal, A. Synlett, 14,(2004), 2533-35	
	7	Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912	
	8	Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484	
	9	Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.